Who
Daniel R. Chevallard
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, LENZ Therapeutics; CFO and COO, Viracta Therapeutics; Chief Financial Officer, Regulus Therapeutics.
In numbers
- Trades disclosed
- 62
- Buys
- 4
- Sells
- 14
- Bought
- $279K
- Sold
- $120K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 10 May 2017
- Last trade
- 27 Mar 2026
- Last filed
- 30 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Mar 2026filed 30 Mar 2026 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $64K7,500 at $8.57 | filing |
| 27 Mar 2026filed 30 Mar 2026 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $64K7,500 at $8.57 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 7 Nov 2025filed 7 Nov 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $45420 at $22.71 | filing |
| 7 Nov 2025filed 7 Nov 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K2,178 at $22.76 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,444 at $0.00 | filing |
| 14 May 2024filed 15 May 2024 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K3,188 at $15.68 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 12 Mar 2024filed 13 Mar 2024 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 27 Feb 2024filed 27 Feb 2024 | Viracta Therapeutics | SEC FORM 4 Sold | $2,4863,405 at $0.73 | filing |
| 25 Feb 2024filed 27 Feb 2024 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code M | —6,889 at $0.00 | filing |
| 25 Feb 2024filed 27 Feb 2024 | Viracta Therapeutics | SEC FORM 4 Code M | —6,889 at $0.00 | filing |
| 28 Nov 2023filed 28 Nov 2023 | Viracta Therapeutics | SEC FORM 4 Sold | $1,8603,720 at $0.50 | filing |
| 25 Nov 2023filed 28 Nov 2023 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code M | —6,889 at $0.00 | filing |
| 25 Nov 2023filed 28 Nov 2023 | Viracta Therapeutics | SEC FORM 4 Code M | —6,889 at $0.00 | filing |
| 28 Aug 2023filed 29 Aug 2023 | Viracta Therapeutics | SEC FORM 4 Sold | $5,0923,512 at $1.45 | filing |
| 25 Aug 2023filed 29 Aug 2023 | Viracta Therapeuticsoption or derivative | SEC FORM 4 Code M | —6,888 at $0.00 | filing |
News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Has Average Target Price of $28.80LENZ · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Daniel R. Chevallard; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.